Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tryton Medical, a developer of stents designed to treat bifurcation lesions, has completed patient recruitment in E-Tryton 150 and E-Tryton Benelux, two European registry studies of the company’s Tryton Side Branch Stent System for the treatment of atherosclerotic lesions in the side branch at the site of a bifurcation.
Subscribe to our email newsletter
The E-Tryton 150 study enrolled 151 patients and E-Tryton Benelux enrolled 155. The primary endpoint of the studies is the overall rate of major adverse cardiac events (MACE) at six months following the procedure.
Reportedly, the studies are also expected to assess the technical success of the Tryton stent, procedural success, and the rate of target lesion revascularization (TLR) at six months after the procedure.
Tryton Medical is conducting various registries in Europe evaluating the Tryton Side Branch Stent System in real-world clinical settings. In addition to E-Tryton 150 and E-Tryton Benelux, E-Tryton Spain (TRES) continues to enroll patients.
Tryton Medical said that more than 1,000 patients in Europe have been treated with the Tryton Side Branch Stent System.
Greg Davis, president and CEO of Tryton Medical, said: “Completion of enrollment in E-Tryton 150 and E-Tryton Benelux are important milestones for Tryton. We look forward to completing enrollment in E-Tryton Spain (TRES) and sharing the real-life practice results of these studies.”